<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Losartan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Losartan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Losartan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10820" href="/d/html/10820.html" rel="external">see "Losartan: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13047" href="/d/html/13047.html" rel="external">see "Losartan: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709020"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When pregnancy is detected, discontinue losartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F190224"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cozaar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867401"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Losartan [DSC];</li>
<li>APO-Losartan [DSC];</li>
<li>Auro-Losartan;</li>
<li>BIO-Losartan [DSC];</li>
<li>Cozaar;</li>
<li>JAMP-Losartan;</li>
<li>MINT-Losartan [DSC];</li>
<li>PMS-Losartan;</li>
<li>Priva-Losartan [DSC];</li>
<li>SANDOZ Losartan;</li>
<li>Septa-Losartan [DSC];</li>
<li>TARO-Losartan [DSC];</li>
<li>TEVA-Losartan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F190269"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiotensin II Receptor Blocker;</li>
<li>
                        Antihypertensive</li></ul></div>
<div class="block doa drugH1Div" id="F190229"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Alternative therapy in patients who cannot tolerate an angiotensin-converting enzyme (ACE) inhibitor (eg, due to cough or angioedema) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304','lexi-content-ref-Guyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304','lexi-content-ref-Guyer.1'])">Ref</a></span>). Angiotensin II receptor blockers (ARBs) do not appear to elevate the risk of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30618189','lexi-content-ref-23147456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30618189','lexi-content-ref-23147456'])">Ref</a></span>); however, patients must be educated that angioedema due to an ACE inhibitor can sometimes reoccur within months following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21970934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21970934'])">Ref</a></span>); referral to an allergist may be appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Non-ST-elevation acute coronary syndrome (alternative agent) (off-label use): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Initiate in stable patients prior to hospital discharge as a component of an appropriate medical regimen, which may include antiplatelet agent(s), a beta-blocker, and a statin. Continue indefinitely for patients with concurrent diabetes, left ventricular ejection fraction ≤40%, hypertension, or stable chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718'])">Ref</a></span>). Dosing is based on general dosing range in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily depending on initial blood pressure; increase dose as tolerated up to 100 mg/day under close monitoring to avoid hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>ST-elevation myocardial infarction (alternative agent) (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In hemodynamically stable patients with large anterior ST-elevation myocardial infarction, consider starting within 24 hours of presentation as a component of an appropriate medical regimen, which may include antiplatelet agent(s), a beta-blocker, and a statin. Continue therapy indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily depending on initial blood pressure; increase dose as tolerated up to 100 mg/day under close monitoring to avoid hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12241832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12241832'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart </b>
<b>failure with reduced ejection fraction (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative therapy in patients who cannot tolerate an angiotensin II receptor-neprilysin inhibitor (ARNI) or an ACE inhibitor (eg, due to cough or angioedema); consultation with a heart failure specialist and/or an allergist may be appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Guyer.1','lexi-content-ref-Meyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Guyer.1','lexi-content-ref-Meyer.1'])">Ref</a></span>). ARBs do not appear to elevate the risk of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30618189','lexi-content-ref-23147456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30618189','lexi-content-ref-23147456'])">Ref</a></span>); however, angioedema due to an ACE inhibitor can sometimes reoccur within months following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21970934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21970934'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily; increase dose (eg, double) every ≥1 to 2 weeks based on response and tolerability to a target dose of 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-19922995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-19922995'])">Ref</a></span>). In hospitalized patients, may titrate more rapidly as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use with another appropriate agent (eg, long-acting dihydropyridine calcium channel blocker or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling) as needed up to 100 mg/day in 1 to 2 divided doses; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9c2e9a4-0ef3-4e42-9cd2-e4fce906acb0">Marfan syndrome with aortic aneurysm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Marfan syndrome with aortic aneurysm</b>
<b> (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Losartan may be used in patients with an aortic aneurysm or with a risk factor for developing an aortic aneurysm; may be used as monotherapy or in combination with a beta-blocker. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 50 mg once daily; after 2 weeks, may increase dose based on blood pressure response and tolerability up to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23999449','lexi-content-ref-25935877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23999449','lexi-content-ref-25935877'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2da94660-189d-42bd-958a-e4286ce477e0">Posttransplant erythrocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttransplant erythrocytosis (kidney transplant recipients) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with a hemoglobin concentration &gt;17 g/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brennan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brennan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily; if inadequate response seen within 4 weeks, may increase to 100 mg once daily based on hemoglobin and blood pressure response; if hemoglobin remains &gt;17 g/dL after an additional 4 weeks, consider alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brennan.1','lexi-content-ref-9621296','lexi-content-ref-9311722','lexi-content-ref-11502994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brennan.1','lexi-content-ref-9621296','lexi-content-ref-9311722','lexi-content-ref-11502994'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d8b6822-d348-4d03-bd66-4ea05b5dd0a9">Proteinuric chronic kidney disease, diabetic or nondiabetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuric chronic kidney disease, diabetic (labeled use) or nondiabetic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily depending on baseline BP; titrate gradually (eg, by doubling the dose every 2 to 4 weeks) up to the maximally tolerated dose, not to exceed 100 mg once daily. If proteinuria target is not met despite optimized dosage, consider additional therapies (eg, sodium-glucose cotransporter-2 inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991077"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18800456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18800456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed (losartan and active metabolite): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10885588','lexi-content-ref-23147456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10885588','lexi-content-ref-23147456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed (losartan and active metabolite): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10761166']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10761166'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988357"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate hepatic impairment: Initial: 25 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">Severe hepatic impairment: There are no specific dosage adjustments provided in the manufacturer’s labeling (has not been studied); initiate therapy at a reduced dosage and titrate as needed. Use with caution in patients with ascites due to cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Mild to severe hepatic impairment or a history of hepatic impairment: Initial: 25 mg once daily</p></div>
<div class="block doe drugH1Div" id="F190230"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F190250"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13047" href="/d/html/13047.html" rel="external">see "Losartan: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Initial: 0.7 mg/kg once daily; maximum initial dose: 50 mg/dose; titrate to desired effect; maximum daily dose: 1.4 mg/kg/<b>day</b> or 100 mg/<b>day</b>; may be administered once daily or divided twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011','lexi-content-ref-15286277','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011','lexi-content-ref-15286277','lexi-content-ref-NIH.1'])">Ref</a></span>); <b>Note:</b> Doses &gt;1.4 mg/kg/<b>day</b> (or &gt;100 mg/<b>day</b>) have not been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15752945','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15752945','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling: </i>Children ≥6 years and Adolescents ≤16 years: Oral: Cozaar prescribing information [Canada]:</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg to &lt;50 kg: Initial: 25 mg once daily; titrate to desired effect; maximum dose: 50 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: Initial: 50 mg once daily; titrate to desired effect; maximum dose: 100 mg/<b>day.</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="adb78e1c-c976-4f71-b011-4afe5202ea6d">Marfan syndrome, aortic-root dilation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Marfan syndrome, aortic-root dilation:</b> Limited data available, optimal place in therapy not defined: Infants ≥6 months, Children, and Adolescents: Oral: Initial: 0.3 to 0.5 mg/kg/<b>day</b> for 21 days, then increase as tolerated to 0.7 to 0.9 mg/kg/<b>day</b> for 21 days, then increase up to 1 to 1.4 mg/kg/<b>day</b>; maximum daily dose: 1.4 mg/kg/<b>day</b> or 100 mg/<b>day</b> (whichever is lower). <b>Note: </b>Dose adjustments (decreased dose and/or frequency) were considered for certain adverse drug reactions (eg, fatigue, dizziness) and lab abnormalities within the study protocol. Dosing based on a large randomized study of patients with Marfan syndrome and a dilated aortic root who were randomized to receive losartan (n=305, ages: 11 ± 6.2 years) or atenolol (n=303, ages: 11.5 ± 6.5 years). Mean losartan dose required was 1.3 ± 0.2 mg/kg/day. Both losartan and atenolol showed a decrease in aortic root z score over a 3-year period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25405392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25405392'])">Ref</a></span>). Similar results were shown in a small, retrospective cohort study (n=18, age: 14 months to 16 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18579813']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18579813'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c59c88d-5cce-4956-a797-c8cf7a3d7160">Proteinuria reduction, chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuria reduction, chronic kidney disease:</b> Limited data available: Children and Adolescents: Oral: Initial: 0.35 to 0.8 mg/kg/dose once daily; maximum initial dose: 50 mg/dose. May increase as tolerated to reduce proteinuria; maximum daily dose: 1.4 mg/kg/<b>day</b> up to 100 mg/<b>day</b>. Dosing based on multiple studies in pediatric patients with proteinuria due to kidney disease either as monotherapy or in combination with ACE inhibitor therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17299000','lexi-content-ref-12915830','lexi-content-ref-15485756','lexi-content-ref-27704256','lexi-content-ref-30284023','lexi-content-ref-20089489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17299000','lexi-content-ref-12915830','lexi-content-ref-15485756','lexi-content-ref-27704256','lexi-content-ref-30284023','lexi-content-ref-20089489'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128490"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: </i>No dosage adjustment necessary unless also volume depleted. If volume depleted, consider initiating at a lower dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>:</i> Not recommended for use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> Not dialyzed (losartan and active metabolite): There are no dosing adjustments in the manufacturer's labeling; based on adult data, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10885588','lexi-content-ref-23147456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10885588','lexi-content-ref-23147456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> There are no dosing adjustments in the manufacturer's labeling; based on adult data, poorly dialyzed and no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10761166']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10761166'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51128491"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: There are no pediatric-specific dosing recommendations provided by the manufacturer; however, based on adult recommendations, a lower initial dose is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosing recommendations provided by the manufacturer (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F54862103"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">May be associated with increased serum creatinine and/or acute kidney injury. Increases in serum creatinine secondary to angiotensin II receptor blockers usually stabilize within 20% to 30% from baseline and are expected; additional increases may indicate renal artery stenosis or volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; inhibits efferent kidney arteriolar vasoconstriction, lowering glomerular filtration pressure which can lead to a modest reduction in glomerular filtration rate (GFR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Expected to be similar to angiotensin-converting enzyme inhibitors: Intermediate; transient increases in serum creatinine generally occur within 2 weeks of initiation and stabilize within 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10724055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10724055'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Sodium or volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18695383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18695383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic and/or nonsteroidal anti-inflammatory drug use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with low renal blood flow (eg, renal artery stenosis) whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia </b>may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; blocks angiotensin II from binding to the adrenal receptor and interferes with generation of angiotensin II within the adrenal cortex, decreasing aldosterone release and impairing kidney potassium excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1855477','lexi-content-ref-21883995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1855477','lexi-content-ref-21883995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Generally occurs within 1 week of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24262001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24262001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High dietary intake of potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline elevated potassium (≥5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications known to decrease renin and aldosterone (eg, direct renin inhibitors, nonsteroidal anti-inflammatory drugs, cyclosporine, tacrolimus, beta-blockers, sulfamethoxazole/trimethoprim, azole antifungals) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20585070','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20585070','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F190188"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences occurred with hypertensive patients unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (&lt;2%), hypotension (type 2 diabetic nephropathy: ≥4%), orthostatic hypotension (type 2 diabetic nephropathy: ≥4%), palpitations (&lt;2%), syncope (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (&lt;2%), skin photosensitivity (&lt;2%), skin rash (&lt;2%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (type 2 diabetic nephropathy: ≥4%; incidence varies in literature and may be impacted by comorbidities) (Desai 2007; Weir 2010; Yusuf 2008), hypoglycemia (type 2 diabetic nephropathy: ≥4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&lt;2%), diarrhea (type 2 diabetic nephropathy: ≥4%), nausea (&lt;2%), vomiting (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (type 2 diabetic nephropathy: ≥4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (type 2 diabetic nephropathy: ≥4%; hypertension: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (&lt;2%), dizziness (3%), drowsiness (&lt;2%), fatigue (type 2 diabetic nephropathy: ≥4%), paresthesia (&lt;2%), sleep disorder (&lt;2%), vertigo (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), asthenia (type 2 diabetic nephropathy: ≥4%), back pain (hypertension and type 2 diabetic neuropathy: 2% to ≥4%), myalgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (ARBs: 3%) (Matchar 2008), dyspnea (&lt;2%), nasal congestion (2%), upper respiratory tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial edema (van Rijnsoever 1998), lip edema (Cha 1999; Kazim 2010), vasculitis (Shalavadi 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (Das 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (Heeringa 1998; Malnick 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Henoch-Schonlein purpura (Bosch 1998; Brouard 2001), thrombocytopenia (Ada 2002; Patel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Al-Halawani 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Kazim 2010), angioedema (Cha 1999; Rivera 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Laryngeal edema (Rivera 1999)</p></div>
<div class="block coi drugH1Div" id="F190204"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to losartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with aliskiren in patients with moderate to severe kidney impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>).</p></div>
<div class="block war drugH1Div" id="F190185"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Angiotensin II receptor antagonists (ARBs) do not appear to elevate the risk of angioedema (Rasmussen 2019; Toh 2012). Patients with a history of angioedema due to an angiotensin-converting enzyme inhibitor must be educated that sometimes there can be recurrence within months following discontinuation (Beltrami 2011). No matter the cause of angioedema, prolonged frequent monitoring is required, especially if tongue, glottis, or larynx are involved, as they are associated with airway obstruction. Discontinue therapy immediately if angioedema occurs. Aggressive early management is critical. IM administration of epinephrine may be necessary. Do not readminister the ARB to patients who experience angioedema from this medication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt or volume depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with losartan.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and kidney function carefully to avoid rapid development of kidney failure (AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment or a history of hepatic impairment; dose adjustment needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution with preexisting kidney insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Race/ethnicity: In Black patients, the BP-lowering effects of ARBs may be less pronounced. The exact mechanism is not known; differences in the renin-angiotensin-aldosterone system, low renin levels, and salt sensitivity more commonly found in Black patients may contribute (Brewster 2013; Helmer 2018; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: In patients on chronic ARB therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). Based on current research and clinical guidelines in patients undergoing noncardiac surgery, continuing ARB is reasonable in the perioperative period. If ARBs are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p></div>
<div class="block foc drugH1Div" id="F190196"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as potassium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cozaar: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cozaar: 50 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cozaar: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F190181"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F190206"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cozaar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $3.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $5.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $6.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Losartan Potassium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.16 - $3.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.17 - $2.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.19 - $3.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867402"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as potassium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cozaar: 25 mg, 50 mg, 100 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block adm drugH1Div" id="F190200"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals; however, administer consistently with respect to food intake at about the same time every day.</p></div>
<div class="block admp drugH1Div" id="F52613191"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered with or without food.</p></div>
<div class="block use drugH1Div" id="F190199"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Management of hypertension in adults and children ≥6 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuric chronic kidney disease, diabetic:</b> Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension.</p></div>
<div class="block off-label drugH1Div" id="F25472738"><span class="drugH1">Use: Off-Label: Adult</span><p>Heart failure with reduced ejection fraction; Marfan syndrome with aortic aneurysm; Non-ST-elevation acute coronary syndrome; Posttransplant erythrocytosis (kidney transplant recipients); Proteinuric chronic kidney disease, nondiabetic; ST-elevation myocardial infarction</p></div>
<div class="block mst drugH1Div" id="F190277"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cozaar may be confused with Colace, Coreg, Hyzaar, Zocor</p>
<p style="text-indent:-2em;margin-left:4em;">Losartan may be confused with lorcaserin, valsartan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F190263"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F190190"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Receptor Blockers may diminish the therapeutic effect of Angiotensin II.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors.  Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Losartan. Management: Consider decreasing the losartan dose and monitoring for evidence of hypotension and worsening renal function if these agents are used in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berberine-Containing Products: May enhance the hypotensive effect of Losartan. Berberine-Containing Products may increase the serum concentration of Losartan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Losartan. CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Losartan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Initiate lithium at lower doses in patients receiving an angiotensin II receptor blocker (ARB). Consider lithium dose reductions in patients stable on lithium therapy who are initiating an ARB. Monitor lithium concentrations closely when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin II Receptor Blockers. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307997"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Avoid use of an angiotensin II receptor blocker (ARB) in patients who may become pregnant and who are not using effective contraception (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. ARBs are fetotoxic. Transition patients prior to conception to an agent preferred for use during pregnancy unless treatment with an ARB is absolutely necessary (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">When an ARB is used for the treatment of proteinuric chronic kidney disease in patients who could become pregnant, discontinue use at the first positive pregnancy test (ADA 2023; Fakhouri 2023)</p></div>
<div class="block pri drugH1Div" id="F190207"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Exposure to an angiotensin II receptor blocker (ARB) during the first trimester of pregnancy may be associated with an increased risk of fetal malformations (ACOG 2019; ESC [Regitz-Zagrosek 2018]).<i></i>Following exposure during the second or third trimesters, drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal kidney function, may lead to fetal lung hypoplasia and skeletal malformations. Oligohydramnios may not appear until after an irreversible fetal injury has occurred. ARB use during pregnancy is also associated with anuria, hypotension, kidney failure, skull hypoplasia, and death in the fetus/neonate. Monitor infants exposed to an ARB in utero for hyperkalemia, hypotension, and oliguria. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Discontinue ARBs as soon as possible once pregnancy is detected. Agents other than an ARB are recommended for the treatment of chronic hypertension during pregnancy (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]). Closely monitor patients exposed to an ARB during pregnancy with serial ultrasounds.</p>
<p style="text-indent:0em;margin-top:2em;">ARBs are not recommended for the treatment of proteinuric chronic kidney disease during pregnancy (Fakhouri 2023).</p></div>
<div class="block brc drugH1Div" id="F190208"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if losartan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. When treatment for hypertension is needed in a breastfeeding patient, consider use of an agent other than an angiotensin II receptor blocker (ESC [Cífková 2020]; NICE 2019).</p></div>
<div class="block dic drugH1Div" id="F190209"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain potassium.</p></div>
<div class="block mop drugH1Div" id="F190194"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure; serum electrolytes (eg, potassium [especially for patients taking concomitant potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts]); serum creatinine; BUN.</p></div>
<div class="block pha drugH1Div" id="F190184"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a selective and competitive, nonpeptide angiotensin II receptor antagonist, losartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; losartan interacts reversibly at the AT1 and AT2 receptors of many tissues and has slow dissociation kinetics; its affinity for the AT1 receptor is 1000 times greater than the AT2 receptor. Angiotensin II receptor antagonists may induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, they do not affect the response to bradykinin, and are less likely to be associated with nonrenin-angiotensin effects (eg, cough and angioedema). Losartan increases urinary flow rate and in addition to being natriuretic and kaliuretic, increases excretion of chloride, magnesium, uric acid, calcium, and phosphate.</p></div>
<div class="block phk drugH1Div" id="F190203"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note: </b>No significant differences in pharmacokinetic parameters have been identified across studied pediatric age groups (6 to 16 years) and adult population.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: ~6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed; slowed with food</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Losartan: 34 L; E-3174 (active metabolite): 12 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: High, &gt;98%; primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic (~14%) via CYP2C9 and 3A4 to active metabolite, E-3174 (10 to 40 times more potent than losartan); extensive first-pass effect</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~33%; AUC of E-3174 (active metabolite) is 4 times greater than losartan; extemporaneously prepared suspension and tablet have similar bioavailability of losartan and E-3174</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Losartan: Children 6 to 16 years: 2.3 ± 0.8 hours; Adults: 2.1 ± 0.7 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">E-3174 (active metabolite): Children 6 to 16 years: 5.6 ± 1.2 hours; Adults: 7.4 ± 2.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Losartan: Children: 2 hours, Adults: 1 hour; E-3174 (active metabolite): Children: 4.1 hours, Adults: 3.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (35%; ~4% as unchanged drug, ~6% as E-3174 [active metabolite]); feces (~60% [oral])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance: Adults:</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Plasma: Losartan: 600 mL/minute; E-3174 (active metabolite): 50 mL/minute</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Renal: Losartan: 75 L/minute; E-3174 (active metabolite): 25 mL/minute</p></div>
<div class="block phksp drugH1Div" id="F51153988"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Plasma concentrations and AUC of losartan and its active metabolite are increased 50% to 90% and renal clearance reduced 55% to 85% in patients with mild (CrCl 50 to 74 mL/minute) and moderate (CrCl 30 to 49 mL/minute) kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma concentrations of losartan are increased 5 times and active metabolite increased 1.7 times in patients with mild to moderate alcoholic cirrhosis. Total plasma clearance of losartan is reduced ~50% and oral bioavailability is about doubled.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Plasma losartan concentrations are about twice as high in hypertensive women as hypertensive men, but plasma concentrations of active metabolite are similar.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F190210"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Hetlosar | Locardia | Losargen | Losart | Lozap | Zargo</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Antipresol | Besubial | Cartan | Casuar | Cozaarex | Enromic | Fabosic | Fada losartan | Fensartan | Fensartan cronos | Fiban | Fraban | Jesan | Klosartan | Loctenk | Loplac | Lorebil | Losacor | Losarlan | Losartan gen med | Losartan Hlb | Losartan labsa | Losartan nexo | Losartan northia | Losartan pfizer | Losartan potasico | Losartan puntanos | Losartan richet | Losartan vannier | Niten | Paxon | Paxon xr | Presimax | Presinor | Prisonil | Tacardia | Tarcane | Temisartan | Tenopres</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cosaar | Losartan | Losartan +Pharma | Losartan Arcana | Losartan G.L. | Losartan krka | Losartan MSD | Losartan pfizer | Losartan stada | Losartan teva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Cozavan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acusan | Angilock | Anin | Anreb | Araten | Cardisan | Cardon | Cozaril | Etan | Larb | Lk | Lohyp | Lok | Lopo | Lopoten | Losa | Losacard | Losan | Losapot | Losar | Losarcar | Losardil | Losarpex | Losart | Losarva | Losatan | Losium | Lospil | Lospre | Lospri | Lotas | Nusartan | Osartan | Osartek | Osartil | Ostan | Parten | Pertilos | Precon | Preslo l | Prosan | Raklok | Renosart | Rosatan | Sarlo | Sb losak | Vasotan | Xelotan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Loortan | Losartan EG | Losartan krka | Losartan pfizer | Losartan potassium accord</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Angizaar | Emtan | Losagen | Losar | Losar denk | Medzar | Medzar fort | Prezar | Zyltan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Hypertonic | Lorista | Losartan | Losartan genericon | Lotar | Lozap | Rasoltan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aradois | Arartan | Cardvita | Corus | Cozaar | Cytrana | Lanzacor | Lorsacor | Losacoron | Losaprin | Losartan potassico | Losartana potassica | Losartec | Losartion | Losatal | Lotanol | Redupress | Torlos | Valtrian | Zaarpress | Zart</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cosaar | Cosaar forte | Cosaar submite | Losartan actavis | Losartan Axapharm | Losartan Helvepharm | Losartan mepha | Losartan sandoz | Losartan Spirig | Losartan spirig hc | Losartan Streuli | Losartan teva | Losartan zentiva | Losartax</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Emtan | Losagen | Losar | Losar denk 100 | Losar denk 25 | Losar denk 50 | Medzarfort | Prezar | Zartan | Zartan fort | Zyltan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aratan | Corodin | Cozaar | Lopren | Losapres | Losarbon | Losartan | Sanipresin | Simperten | Valinor</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei yi | Cozaar</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ancor | Angiobloq | Aralox | Arapres | Arapres anzg | Artana | Convertal | Cotasar | Cozaar | Expopress | Karplan | L card | Lopren | Losakem | Losanorm | Losarbay | Losartan | Losartan denk | Losartan potasico | Lozarten | Medsart | Myotan | Sarmed | Satoren | Tensartan | Tensofar | Tensypres k</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo losartan | Arionex | Cozaar | Lakea | Lorista | Losartan | Losartan aurobindo | Losartan Bluefish | Losartan krka | Losartan Orion | Losartan stada | Losartan teva | Losartic | Lozap | Nopretens | Sangona | Sidok</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lorzaar | Lorzaar protect | Losar Q | Losar Teva | Losargamma | Losartan 1A Pharma | Losartan aaa | Losartan AbZ | Losartan Acis | Losartan actavis | Losartan AL | Losartan Aristo | Losartan Atid | Losartan axiromed | Losartan Biomo | Losartan CT | Losartan Dura | Losartan Hennig | Losartan Heumann | Losartan Hexal | Losartan Hormosan | Losartan Kalium Axcount | Losartan kalium pfizer | Losartan kalium puren | Losartan kalium volkspharma | Losartan Ratiopharm | Losartan sandoz | Losartan stada | Losartan Steiner | Losartan Winthrop | Losartan-Kalium Axcount | Losartan-Kalium Basics | Losartan-Kalium Beta | Losartan-Kalium Bluefish | Losartan-Kalium Orifarm | Losartan-kalium TAD</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Ancozan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Accord | Angibloc | Avantar | Cardioram | Cardizaar | Covance | Cozaar | Doxalam | Eurolosart | Iberclofam | Klovat | Losacor | Losartan | Losartan Feltrex | Losartan Lam | Losartan MK | Losartan potasico | Losartan wemed | Losartas | Nefrotal | Paxon | Presidol | Presotan | Renotensyl | Rodicard | Satoren | Tamisen | Triatec | Valpresor</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Angiolow | Angioten | Arados | Cardiodan | Cardiostar 100 | Cardiostar 50 | Cardiovasc | Convertal | Corodin | Covance | Cozaar | Italsartan | Lodestar | Losarbon | Losartan | Losartan la sante | Losartan potasico | Lostab | Myocord | Nefrotal | Rasertan | Riocel | Satoren | Simperten | Soolan | Zart</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lorista | LOSARTAN ACCORD | Losartan actavis | Lozap</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amosar | Aratins | Cozaar | Kanzar | Losar | Losarmepha | Losartan | Lostapressin | Lozapress | Remtozar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Cozaar inicio | Lavestra | Losartan | Losartan Acost | Losartan actavis | Losartan Almus | Losartan Alter | Losartan Asol | Losartan Bexal | Losartan Cinfa | Losartan Combix | Losartan Davur | Losartan Edigen | Losartan Kern Pharma | Losartan Korhispana | Losartan Lareq | Losartan mabo | Losartan Normon | Losartan Pensa | Losartan pharma combix | Losartan Pharmacia | Losartan Pharmagenus | Losartan ranbaxy | Losartan ratio | Losartan Ratiopharm | Losartan sandoz | Losartan Silanes | Losartan stada | Losartan Sumol | Losartan Tecnigen | Losartan teva | Losartan UR | Losartan Vir | Losartan Winthrop</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Czartan | Losar denk 100 | Losar denk 25 | Losar denk 50 | Losarva | Losium | Zyltan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Losafarm | Losarstad | Losartan actavis | Losartan agp | Losartan krka | Losartan orifarm | Losartan Orion | Losartan pfizer | Losartan ranbaxy | Losartan teva | Losatrix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Losartan actavis | Losartan Almus | Losartan Alter | Losartan Arrow Generiques | Losartan Biogaran | Losartan Bouchara Recordati | Losartan Cristers | Losartan EG | Losartan Evolugen | Losartan intas | Losartan Isomed | Losartan krka | Losartan mylan | Losartan pfizer | Losartan phr lab | Losartan Qualimed | Losartan ranbaxy | Losartan Ratiopharm | Losartan sandoz | Losartan teva | Losartan Winthrop | Losartan Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Losartan | Losartan potasssium | Zovencal</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Lorpam</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Cozapert | Golasan | Hypozar | Loben | Lorfast | Lorotens | Losadrac | Losalet | Losarb | Lozanel | Lozatan | Lyosan | Mozartan | Ozarium | Press Down | Proelsartan | Rabolan | Rapifast</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Losarac</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo losartan | Cozaar | Emlosar | Lopress | Lorista | Losacor | Losanorm | Losartan | Losartan stada | Losartan tiasar | Lostad T50 | Osartil | Vick Losartan | Zaart | Zyltan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lakea | Lorista | Losartan genera | Losartic | Lotan | Lotar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Arbartan | Artager | Cozaar | Lavestra | Losartan 1 A Pharma | Losartan krka | Losartan Ratiopharm | Lozarep | Portiron | Prelow | Stadazar | Tervalon</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Acetensa | Angioten | Cozaar | Insaar | Koinsar | Lifezar | Losartan | Santesar | Sartaxal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cosartal | Cozaar | Cozatan | Losartan | Losartan KRKA | Losartan rowa | Losartan teva | Lotanos | Lozitar | Myzaar | Solvatan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Losardex | Losarta | Lotan | Ocsaar</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alsar | Alsartan | Angilo | Angireb | Angizaar | Asart | Atzaar | Biosartan | Biozaar | Bp cure | Cardikare | Cosart | Covance | Cozar | Czar | Czartan | Giftan | Ht Norm | Icosar | Lanxes | Lara | Lartan | Lo | Loar | Lolek | Lopassium | Lopt | Lorsave | Losacar | Losagard | Losain | Losakind | Losalife | Losamax | Losan | Losanorm | Losar | Losaral | Losarmed | Losartas | Losasun | Losatec | Losatrust | Losavas | Loscom | Losfirst | Losgard | Losium | Lospot | Lostat | Lot | Lotace | Lotak | Lotas | Lotop | Lozitan | Ltk | Miotin | Myotan | Nusar | Nuzar | Omnitan | Pozaar | Presartan | Relate | Repace | Resilo | Revas | Rigard | Sarpot | Tozaar | Vazortan | Zaart | Zargo | Zarlo | Zilos | Zyltan</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">L sartan | Losart</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Lopress | Presmin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dalosar | Lastan | Lorista | Lortaan | Losahyp | Losaprex | Losartan Acv | Losartan AHCL | Losartan Almus | Losartan Ate | Losartan aurobindo | Losartan Doc | Losartan dr reddy's | Losartan EG | Losartan Ger | Losartan Myl | Losartan pfizer | Losartan Pns | Losartan Ran | Losartan Tecnigen | Losartan Tev | Losartan Wpi | Neo lotan | Precten</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Azarten | Cozaar | Lacine | Losart</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Losartan k | Losartan K Nissin | Losartan potasium ffp | Losartan potassium jg | Losartan potassium teva | Nu lotan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alsartan | Angilock | Angisartan | Angitan | Angizaar | Bepsar | Carditan | Cozaar | Dinlaar | Lorsa | Lortan | Losacar | Losagen | Losakind | Losangio | Losapress | Losar | Losar denk | Losartan | Losartas | Losatec | Lozart | Normopress | Nusar | Presartan | Prosan | Repace | Reten | Sartilos | Tozaar | Xartan | Zaart | Zyltan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arb | Arbitan | Aukostan | Azertan | Bearotan | Br sartan | Caroza | Casatan | Celsartan | Ceroz | Cezar | Cmg Losartan | Colosa | Coroza | Cortan da | Cosal | Cosaltan | Cosarotan | Cosartan | Cosca | Cozaar | Cozahu | Cozaril | Cozarotan | Cozarsaltan | Cozartan | Cozasartan | Cozatan | Elsartan | Elzatan | Frosatan | Hanlim losartan | Huniz losartan potassium | Hysaltan | Ilyangbio losartan potassium | Inno.n losartan | Jw lozaltan | Kosartan | Kozanew | Ksaltan | Kuhnil losartan potassium | Kukje losartan | L sartan | Local | Locatan | Loders | Loiza | Losa K | Losacatan | Losaco | Losain | Losal | Losamax | Losapa | Losar | Losar v | Losargen | Losaridon | Losarmax | Losarpin | Losartal | Losartam | Losartan | Losartan cj | Losartan Han All | Losartin | Losastar | Losat | Losata | Losatal | Losatam | Losatan | Losatan i | Losatin | Losato | Lositan | Lositen | Lotan | Lotazin | Lotein | Lozacal | Lozarsin | Lozasartan | Lozata | Lozatal | Lozet | Loziten | Luzatan | Medilosa | Mothers Rosa | New losar | Newcosar | Newrosar | Newrosatan | Nurotan | Osartan | Rocatan | Rocotan | Rosa | Rosabel | Rosain | Rosarin | Rosarzen | Rosat | Rosawin | Roza | Rozentan | Rp losa | Salotan | Salotin | Sarlotan | Sezar | Simsatan | Taiguk losartan | Vicoza | Wonsartan | Zaratan | Zarotan | Zartan | Zerosaltan | Zerosartan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Losart | Sartan | Sortiva</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lacine | Losanet | Losart | Losartan | Losartan Biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Covance | Cozaar | Lorista | Losacor | Losartan Ingen Pharma | Losartan krka | Lozap | Sartens | Tarnasol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Loortan | Losartan EG | Losartan Ratiopharm</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Covance | Cozaar | Lorista | LOSARTAN ACCORD | Lozap | Sartens</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acard | Ancine | Anginib | Aratens | Avazar | Cozaar | Lacine | Losartan Gt | Medzar | Prezar | Rosar | Tanzaar | Vizartan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Accolok | Alderan | Ara 2 | Athakare | Bicardren | Bimidal | Cimaher | Colibs | Conciluk | Corperia | Cozaar | Frensodol | Jomasar | Leny | Leverstat | Lodestar | Lopred | Losartan | Losartan genplus | Losartan landsteiner | Lospotar | Lozydel | Miniter | Plavisin | Punab | Ratnat | Saravanta | Sartadem | Staars | Takilpam | Targancil | Tasico | Viopexa</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Covance | Cozaar | Lorista | Losacar | Losagen | Losartan | Losartan stada | Losartas | Presartan | Rasoltan | Rosal | Rosart | Saranto | Tanzaril | Tosan | Tozaar | Zosaar | Zylovaa | Zyltan</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Arbitense | Bloctran | Hetlosar | Loryza | Losakind | Losarmax 50 | Losartan | Losartan makinga | Losrtec | Lotan | Meem losartan | Multichris losartan potassium | Myotan | Nusar | Ocepress | Rosart | Skg losartan | Xavor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Entrizen | Kaliumlosartan | Kaliumlosartan Actavis | Kaliumlosartan ratiopharm | Kaliumlosartan Sandoz | Losanox | Losartan | Losartan Kalium Cf | Losartan Kalium Ranbaxy | Losartankalium | Losartankalium accord | Losartankalium Apotex | Losartankalium Aurobindo | Losartankalium Mylan | Losartankalium PCH | Losartankalium xiromed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Cozaar start | Losartan krka | Losartan medic valley | Losartan orifarm | Losartan teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Losartan actavis | Lostaar</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Angizaar | Aratan | Artan | Artanbix | Camir | Cardiovital | Cormac | Corodin | Covance | Cozaar | Czartan | Hyperan | Locarmec | Lortan | Losacor | Losadel | Losapresan | Losarbon | Losaren | Losarquilab | Losartan | Losartan potasico | Nusar | Pressaliv | Resilo | Rifex | Simperten</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">A.R.A | Actizar | Angel 50 | Angioten | Angisartan | Anin | Anzar | Arbloc | Artal | Baczartan | Bepsar | Besartan | Cardizar | Congezar | Cotenace | Cozaar | Doxar | Dylaran | Ecozar | Ekosart | Eseflah | Ezartan | Getzar | Gosartan | Hartzar | Hextan | Hylos | Hypertan | Hyperthree | Jensar | Kardiostan | Kenzar | Ksart | Lanzaar | Lifezar | Lipewin | Lobip | Lortan | Losaar | Losacar | Losagan | Losakind | Losangio | Losar | Losarcure | Losargard | Losark | Losarniel | Losart | Losartan | Losartan Winthrop | Losavas | Losium | Lostar | Lozaar | Lozart | Medzart | Moxifast | Myotan | Mysartan | Myzar | Natrasol | Natrazol | Neosartan | Nipartan | Normoten | Parten | Pharex Losartan | Presartan | Prestan | Prolostan | Provizar | Prozar | Q pid | Quezar | Ritemed Losartan | Saranto | Sartan | Scilosar | Sydentan | Torlos | Vamzar | Vivasartan | Xartan | Zaran | Zarnat | Zarphil | Zarpose | Zartan s | Zarten | Zeftan | Zilzart</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A2a | Aceartin | Acozar | Actilop | Actitar | Bepsar | Blaze | Co actitar | Corik | Corus | Coryton | Cozaar | Eziday | Giozar | Kosart | Kulb | Larsen | Lastron | Locor | Lopec | Losaan | Losafast | Losar-k | Losartan | Losartec | Losartin | Losascot | Losaten | Losium | Lostress | Lot | Lotansin | Lotar | Lotense | Lozarta | Lozatin | Loze | Megasar | Normopress | Osran | Sar-k | Sarcol | Sartan | Stumpan | Tansin | Teslo | Traslo | Vezaar | Welsar k | Xavor | Xeta | Zonate | Zosartan-k | Zostat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo Lozart | Cozaar | Lakea | Loreblok | Lorista | Losacor | Losagen | Losargamma | Losartan arrow | Losartan Bluefish | Losartan genoptim | Losartan krka | Losartan pfizer | Losartan Ratiopharm | Losartanum 123ratio | Losartic | Lozap | Presartan | Rasoltan | Sortabax | Stadazar | Xartan | Zeprez</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cozaar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aratis Farbio | Cozaar | Decara | Lortaan | Losartan | Losartan Almus | Losartan aurobindo | Losartan aurovitas | Losartan Azevedos | Losartan bluepharma | Losartan daquimed | Losartan mepha | Losartan mylan | Losartan tecnimede | Losartan Wynn</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Accord | Convertal | Coronovo | Disgrenol | Fabosic | Gadotensil | Hecordil | Hiperaltam | Hipercor | Latral | Losartan bioethic pharma | Losartan millet | Losartan nl pharma | Lozax | Rhytmus | Simperten | Temlosal | Tensofar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lacine | Losanet | Losart | Sartan | Sortiva | Sortiva Forte</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lorista | Lozap | Talosan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bloctran | Bloktran | Brozaar | Cardomin sanovel | Cozaar | Karsartan | Lakea | Lorista | Losacor | Losap | Losarel | Losartan | Losartan akrikhin | Losartan canon | Losartan macleods | Losartan richter | Losartan teva | Lotor | Lozap | Presartan | Renicard | Vasotens | Vazotenz | Vero losartanum | Zysacar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo losartan | Azar | Cozaar | Lacine | Pms losartan | Sartan | Sortiva | Stravis</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Klomentan | Losarstad | Losartan actavis | Losartan agp | Losartan aurobindo | Losartan Bluefish | Losartan jubilant | Losartan krka | Losartan mylan | Losartan orifarm | Losartan pfizer | Losartan sandoz | Losartan teva | Losatrix | Lostankal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Angizaar | Cozaar | Losagen | Losartan | Losartan Hexal | Losartas | Lozarsin fc | Rosart | Sartocad</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lorista | Losartan Alkaloid | Losartan mylan | Losartic | Lotar | Rasoltan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Asortek | Cozaar | Lakea | Lorista | Losartan Bluefish | Losartan krka | Losartan Orion | Losartan stada | Losartan teva | Losartan zentiva | Lozap</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Lanzaar | Loranta | Losacar | Losartan | Tanzaril | Tosan</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Losar | Losartan Winthrop | Medzar | Zartan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cozaar | Eklips | Felow | Hilos | Losartil | Loxibin | Pensartan | Sarilen | Sarvas</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cosar fc | Coxco | Cozaar | Depressor | Hetlosar | Kinzaar | Losacar | Losapin | Losart | Losartan | Losartan cyh | Losartan teva | Losater | Losenta | Lostan | Lowtan | Lowten | Sluxdin | Zosaa | Zosatan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Angizaar | Brozaar | Cardomin | Cozaar | Erinorm | Hyperzar | Klosart | Lorista | Losakar | Losar | Losartan | Losartan sandoz | Losartan teva | Losartin | Lotar | Lozap | Lozar | Presartan | Sentor</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Angizaar | Losaberg | Losacar | Losagen | Losar denk 100 | Losar denk 50 | Losartas | Losium | Presartan | Sartan | Tozaar | Vazortan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Angiopal | Cartan | Convertal | Losartan potasico | Losartan potasico opko | Loxar | Ras | Regulapres | Tensilar</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alvotinox | Angilock | Biortan | Biosartan | Cormac | Cozaar | Leny | Losarlab p | Losartan | Losartan potasico | Losartana potassica | Losartol | Losawell | Nefrotal | Ofapres | Presartan | Redyscar | Sortal | Sutralar | Tenserpil</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Fatedia | Lostad t100 | Nerazzu | Nonanti | Sartanpo | Savi losartan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Auro losartan | Austell Losartan | Cipla Losartan | Ciplazar | Cozaar | Hytenza | Los-arb | LOSARTAN ACCORD | Losartan biotech | Losartan macleods | Losartan unicorn | Lozaan | Normoten | Renicard | Spec Losartan | Zaario | Zartan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Losa | Losakind | Losar | Losar denk 100 | Losar denk 25 | Losar denk 50 | Nusar | Presartan | Tozaar | Vazortan | Zyltan</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Losagen | Losar | Losartas | Presartan | Tozaar 50</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12379089">
<a name="12379089"></a>Ada S, Yalamanchili M, Friedenberg W. Immune thrombocytopenia after losartan therapy. <i>Ann Intern Med</i>. 2002;137(8):704. doi:10.7326/0003-4819-137-8-200210150-00032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/12379089/pubmed" id="12379089" target="_blank">12379089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25374869">
<a name="25374869"></a>Al-Halawani MZ, Thawabi M, Asslo F, Shaaban H, Shamoon F, Baddoura WJ. Losartan-induced ischemic hepatocellular hepatotoxicity: a case report and literature review. <i>J Family Med Prim Care</i>. 2014;3(3):272-274. doi:10.4103/2249-4863.141635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25374869/pubmed" id="25374869" target="_blank">25374869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2020. <i>Diabetes Care</i>. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S280. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed April 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20585070">
<a name="20585070"></a>Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. doi:10.1001/archinternmed.2010.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/20585070/pubmed" id="20585070" target="_blank">20585070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bakris.1">
<a name="Bakris.1"></a>Bakris GL. Treatment of diabetic nephropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bakris.2">
<a name="Bakris.2"></a>Bakris GL. Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10724055">
<a name="10724055"></a>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. <i>Arch Intern Med</i>. 2000;160(5):685-693. doi:10.1001/archinte.160.5.685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/10724055/pubmed" id="10724055" target="_blank">10724055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21970934">
<a name="21970934"></a>Beltrami L, Zanichelli A, Zingale L, Vacchini R, Carugo S, Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema.<i> J Hypertens</i>. 2011;29(11):2273-2277. doi: 10.1097/HJH.0b013e32834b4b9b.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/21970934/pubmed" id="21970934" target="_blank">21970934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9448560">
<a name="9448560"></a>Bosch X. Henoch-Schönlein purpura induced by losartan therapy. <i>Arch Intern Med</i>. 1998;158(2):191-192. doi:10.1001/archinte.158.2.191-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/9448560/pubmed" id="9448560" target="_blank">9448560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brennan.1">
<a name="Brennan.1"></a>Brennan DC, Vlahakos DV. Erythrocytosis following renal transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23721258">
<a name="23721258"></a>Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. <i>BMC Med</i>. 2013;11:141. doi:10.1186/1741-7015-11-141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23721258/pubmed" id="23721258" target="_blank">23721258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18579813">
<a name="18579813"></a>Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome. <i>N Engl J Med</i>. 2008;358(26):2787-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/18579813/pubmed" id="18579813" target="_blank">18579813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11531817">
<a name="11531817"></a>Brouard M, Piguet V, Chavaz P, Borradori L. Schönlein-Henoch purpura associated with losartan treatment and presence of antineutrophil cytoplasmic antibodies of x specificity. <i>Br J Dermatol</i>. 2001;145(2):362-363. doi:10.1046/j.1365-2133.2001.04361.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/11531817/pubmed" id="11531817" target="_blank">11531817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16133038">
<a name="16133038"></a>Butani L. Angiotensin Blockade in Children With Chronic Glomerulonephritis and Heavy Proteinuria. <i>Pediatr Nephrol</i>. 2005;20(11):1651-1654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/16133038/pubmed" id="16133038" target="_blank">16133038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDA.1">
<a name="CDA.1"></a>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. <i>Can J Diabetes</i>. 2013;35(suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10492494">
<a name="10492494"></a>Cha YJ, Pearson VE. Angioedema due to losartan. <i>Ann Pharmacother</i>. 1999;33(9):936-938. doi:10.1345/aph.18396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/10492494/pubmed" id="10492494" target="_blank">10492494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17299000">
<a name="17299000"></a>Chandar J, Abitbol C, Montané B, et al. Angiotensin Blockade as Sole Treatment for Proteinuric Kidney Disease in Children. <i>Nephrol Dial Transplant</i>. 2007;22(5):1332-1337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/17299000/pubmed" id="17299000" target="_blank">17299000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,” <i>JAMA</i>, 2003, 289(19):2560-2571.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cozaar.1">
<a name="Cozaar.1"></a>Cozaar (losartan) [prescribing information]. Jersey City, NJ: Organon LLC; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cozaar.2">
<a name="Cozaar.2"></a>Cozaar (losartan) [product monograph]. Kirkland, QC, Canada: Organon Canada Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11937178">
<a name="11937178"></a>Dahlöf B, Devereux RB, Kjeldsen SE, et al, "Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol," <i>Lancet</i>, 2002, 359(9311):995-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/11937178/pubmed" id="11937178" target="_blank">11937178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26816476">
<a name="26816476"></a>Das S, Bandyopadhyay S, Ramasamy A, Prabhu VV, Pachiappan S. A case of losartan-induced severe hyponatremia. <i>J Pharmacol Pharmacother</i>. 2015;6(4):219-221. doi:10.4103/0976-500X.171880<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/26816476/pubmed" id="26816476" target="_blank">26816476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17996561">
<a name="17996561"></a>Desai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. <i>J Am Coll Cardiol</i>. 2007;50(20):1959-1966. doi:10.1016/j.jacc.2007.07.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/17996561/pubmed" id="17996561" target="_blank">17996561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12241832">
<a name="12241832"></a>Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan. <i>Lancet</i>. 2002;360(9335):752-760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/12241832/pubmed" id="12241832" target="_blank">12241832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15485756">
<a name="15485756"></a>Ellis D, Moritz ML, Vats A, et al. Antihypertensive and Renoprotective Efficacy and Safety of Losartan. A Long-Term Study in Children With Renal Disorders. <i>Am J Hypertens</i>. 2004;17(10):928-935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/15485756/pubmed" id="15485756" target="_blank">15485756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12915830">
<a name="12915830"></a>Ellis D, Vats A, Moritz ML, et al. Long-Term Antiproteinuric and Renoprotective Efficacy and Safety of Losartan in Children With Proteinuria. <i>J Pediatr</i>. 2003;143(1):89-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/12915830/pubmed" id="12915830" target="_blank">12915830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36481180">
<a name="36481180"></a>Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. <i>Kidney Int</i>. 2023;103(2):264-281. doi:10.1016/j.kint.2022.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/36481180/pubmed" id="36481180" target="_blank">36481180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070666">
<a name="25070666"></a>Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation.</i> 2014;130:1749-1767. doi:10.1161/CIR.0000000000000095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25070666/pubmed" id="25070666" target="_blank">25070666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085961">
<a name="25085961"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25085961/pubmed" id="25085961" target="_blank">25085961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29192011">
<a name="29192011"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/29192011/pubmed" id="29192011" target="_blank">29192011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. Published online November 15, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23999449">
<a name="23999449"></a>Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.<i> Eur Heart J.</i> 2013;34(45):3491-3500. doi:10.1093/eurheartj/eht334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23999449/pubmed" id="23999449" target="_blank">23999449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guyer.1">
<a name="Guyer.1"></a>Guyer AC, Banerji A. ACE inhibitor-induced angioedema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653007">
<a name="9653007"></a>Heeringa M, van Puijenbroek EP. Reversible dysgeusia attributed to losartan. <i>Ann Intern Med</i>. 1998;129(1):72. doi:10.7326/0003-4819-129-1-199807010-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/9653007/pubmed" id="9653007" target="_blank">9653007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808707">
<a name="29808707"></a>Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. <i>Ann Pharmacother</i>. 2018;52(11):1143-1151. doi:10.1177/1060028018779082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/29808707/pubmed" id="29808707" target="_blank">29808707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(23):2610-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10835064">
<a name="10835064"></a>Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE).<i> Pediatrics</i>. 2000;105(6):1242-1249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/10835064/pubmed" id="10835064" target="_blank">10835064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322642">
<a name="36322642"></a>Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. <i>Circulation.</i> 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/36322642/pubmed" id="36322642" target="_blank">36322642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. Published online December 18, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. Published online March 28, 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9621296">
<a name="9621296"></a>Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. <i>J Am Soc Nephrol.</i> 1998;9(6):1104-1108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/9621296/pubmed" id="9621296" target="_blank">9621296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20726206">
<a name="20726206"></a>Kazim SF, Shahid M. Losartan associated anaphylaxis and angioneurotic oedema. <i>J Pak Med Assoc</i>. 2010;60(8):685-686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/20726206/pubmed" id="20726206" target="_blank">20726206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.<i> Kidney Int.</i> 2021b;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018935">
<a name="25018935"></a>Kidney Disease: Improving Global Outcomes (KDIGO). Chapter 10: Immunoglobulin A nephropathy.<i> Kidney Int Suppl (2011).</i> 2012;2(2):209-217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25018935/pubmed" id="25018935" target="_blank">25018935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36272764">
<a name="36272764"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2022;102(suppl 5):S1-S127. doi:10.1016/j.kint.2022.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/36272764/pubmed" id="36272764" target="_blank">36272764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int</i>. 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl (2013)</i>. 2013;3(1):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1855477">
<a name="1855477"></a>Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. <i>Endocrinology</i>. 1991;129(2):823-831. doi:10.1210/endo-129-2-823<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/1855477/pubmed" id="1855477" target="_blank">1855477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9311722">
<a name="9311722"></a>Klaassen RJ, van Gelder T, Rischen-Vos J, Deinum J, Man in’t Veld AJ, Weimar W. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. <i>Transplantation</i>. 1997;64(5):780-782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/9311722/pubmed" id="9311722" target="_blank">9311722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23176216">
<a name="23176216"></a>Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. <i>Curr Pharm Des</i>. 2013;19(17):3033-3042. doi:10.2174/1381612811319170009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23176216/pubmed" id="23176216" target="_blank">23176216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19922995">
<a name="19922995"></a>Konstam MA, Neaton JD, Dickstein K; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. <i>Lancet.</i> 2009;374(9704):1840-1848.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/19922995/pubmed" id="19922995" target="_blank">19922995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25405392">
<a name="25405392"></a>Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. <i>N Engl J Med</i>. 2014;371(22):2061-2071.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25405392/pubmed" id="25405392" target="_blank">25405392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16909244">
<a name="16909244"></a>Litwin M, Grenda R, Sladowska J, et al. Add-On Therapy With Angiotensin II Receptor 1 Blocker in Children With Chronic Kidney Disease Already Treated With Angiotensin-Converting Enzyme Inhibitors. <i>Pediatr Nephrol</i>. 2006;21(11):1716-1722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/16909244/pubmed" id="16909244" target="_blank">16909244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11104435">
<a name="11104435"></a>Malnick SD, Becker S. Dysgeusia by losartan in a patient intolerant of captopril. <i>MedGenMed</i>. 1999;E33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/11104435/pubmed" id="11104435" target="_blank">11104435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2">
<a name="Mann.2"></a>Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17984484">
<a name="17984484"></a>Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. <i>Ann Intern Med</i>. 2008;148(1):16-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/17984484/pubmed" id="17984484" target="_blank">17984484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyer.1">
<a name="Meyer.1"></a>Meyer TE. Primary pharmacologic therapy of heart failure with reduced ejection fraction in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25935877">
<a name="25935877"></a>Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial.<i> Eur Heart J.</i> 2015;36(32):2160-2166. doi:10.1093/eurheartj/ehv151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25935877/pubmed" id="25935877" target="_blank">25935877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295051">
<a name="15295051"></a>Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>N Engl J Med</i>. 2004;351(6):585-592. doi:10.1056/NEJMra035279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/15295051/pubmed" id="15295051" target="_blank">15295051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24262001">
<a name="24262001"></a>Park IW, Sheen SS, Yoon D, et al. Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?. <i>J Clin Pharm Ther</i>. 2014;39(1):61-68. doi:10.1111/jcpt.12109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/24262001/pubmed" id="24262001" target="_blank">24262001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23856430">
<a name="23856430"></a>Patel DK, Bilkha N, Schnee D. Angiotensin II type 1 receptor blocker-induced immune thrombocytopenia: a case report. <i>J Med Case Rep</i>. 2013;7:183. doi:10.1186/1752-1947-7-183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23856430/pubmed" id="23856430" target="_blank">23856430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10761166">
<a name="10761166"></a>Pedro AA, Gehr TW, Brophy DF, Sica DA. The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. <i>J Clin Pharmacol</i>. 2000;40(4):389-395. doi:10.1177/00912700022009099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/10761166/pubmed" id="10761166" target="_blank">10761166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883995">
<a name="21883995"></a>Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cardiovasc Ther</i>. 2012;30(3):e156-e166. doi:10.1111/j.1755-5922.2010.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/21883995/pubmed" id="21883995" target="_blank">21883995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30618189">
<a name="30618189"></a>Rasmussen ER, Pottegård A, Bygum A, von Buchwald C, Homøe P, Hallas J. Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study. <i>J Intern Med.</i> 2019;285(5):553-561. doi:10.1111/joim.12867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/30618189/pubmed" id="30618189" target="_blank">30618189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10492493">
<a name="10492493"></a>Rivera JO. Losartan-induced angioedema. <i>Ann Pharmacother</i>. 1999;33(9):933-935. doi:10.1345/aph.18350<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/10492493/pubmed" id="10492493" target="_blank">10492493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27704256">
<a name="27704256"></a>Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G. Achieving remission of proteinuria in childhood CKD. <i>Pediatr Nephrol</i>. 2017;32(2):321-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/27704256/pubmed" id="27704256" target="_blank">27704256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.1">
<a name="Runyon.1"></a>Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed January 4, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695383">
<a name="18695383"></a>Ryan MJ, Tuttle KR. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?. <i>Curr Opin Nephrol Hypertens</i>. 2008;17(5):443-449. doi:10.1097/MNH.0b013e32830a9606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/18695383/pubmed" id="18695383" target="_blank">18695383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11602506">
<a name="11602506"></a>Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <i>Circulation</i>. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/11602506/pubmed" id="11602506" target="_blank">11602506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15752945">
<a name="15752945"></a>Shahinfar S, Cano F, Soffer BA, et al. A Double-Blind, Dose-Response Study of Losartan in Hypertensive Children. <i>Am J Hypertens</i>. 2005;18(2, pt 1):183-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/15752945/pubmed" id="15752945" target="_blank">15752945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shalavadi.2015">
<a name="Shalavadi.2015"></a>Shalavadi MH, Mangannavar CV, Medepalli P. Losartan induced vasculitis and anaemia: a case report in tertiary care hospital. <i>Indian Journal of Pharmacy Practice</i>. 2015;8(4):196-198. doi:10.5530/ijopp.8.4.9</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30284023">
<a name="30284023"></a>Shima Y, Nakanishi K, Sako M, et al. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). <i>Pediatr Nephrol</i>. 2019;34(5):837-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/30284023/pubmed" id="30284023" target="_blank">30284023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10885588">
<a name="10885588"></a>Sica DA, Halstenson CE, Gehr TW, Keane WF. Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. <i>Clin Pharmacokinet</i>. 2000;38(6):519-526. doi:10.2165/00003088-200038060-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/10885588/pubmed" id="10885588" target="_blank">10885588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18800456">
<a name="18800456"></a>Sica DA, Lo MW, Shaw WC, et al. The pharmacokinetics of losartan in renal insufficiency. <i>J Hypertens Suppl</i>. 1995;13(1):S49-S52. doi:10.1097/00004872-199507001-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/18800456/pubmed" id="18800456" target="_blank">18800456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147456">
<a name="23147456"></a>Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. <i>Arch Intern Med</i>. 2012;172(20):1582-1589. doi:10.1001/2013.jamainternmed.34<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23147456/pubmed" id="23147456" target="_blank">23147456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9461241">
<a name="9461241"></a>Toto R, Shultz P, Raij L, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. <i>Hypertension</i>. 1998;31(2):684-691. doi:10.1161/01.hyp.31.2.684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/9461241/pubmed" id="9461241" target="_blank">9461241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9778207">
<a name="9778207"></a>van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. <i>Arch Intern Med</i>. 1998;158(18):2063-2065. doi:10.1001/archinte.158.18.2063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/9778207/pubmed" id="9778207" target="_blank">9778207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20089489">
<a name="20089489"></a>Webb NJ, Lam C, Loeys T, et al. Randomized, double-blind, controlled study of losartan in children with proteinuria. <i>Clin J Am Soc Nephrol</i>. 2010;5(3):417-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/20089489/pubmed" id="20089489" target="_blank">20089489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10619572">
<a name="10619572"></a>Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?. <i>Am J Hypertens</i>. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/10619572/pubmed" id="10619572" target="_blank">10619572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20150448">
<a name="20150448"></a>Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. <i>Clin J Am Soc Nephrol</i>. 2010;5(3):531-548. doi:10.2215/CJN.07821109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/20150448/pubmed" id="20150448" target="_blank">20150448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. <i>Hypertension. </i>2018;71(6):e13-e115<i>. </i>doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12920631">
<a name="12920631"></a>White CT, Macpherson CF, Hurley RM, et al. Antiproteinuric Effects of Enalapril and Losartan: A Pilot Study. <i>Pediatr Nephrol</i>. 2003;18(10):1038-1043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/12920631/pubmed" id="12920631" target="_blank">12920631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23741058">
<a name="23741058"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/23741058/pubmed" id="23741058" target="_blank">23741058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461007">
<a name="28461007"></a>Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>J Am Coll Cardiol.</i> 2017;70(6):776-803. doi:10.1016/j.jacc.2017.04.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/28461007/pubmed" id="28461007" target="_blank">28461007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11502994">
<a name="11502994"></a>Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. <i>Transplantation</i>. 2001;72(3):542-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/11502994/pubmed" id="11502994" target="_blank">11502994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378520">
<a name="18378520"></a>Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med</i>. 2008;358(15):1547-1559. doi:10.1056/NEJMoa0801317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/18378520/pubmed" id="18378520" target="_blank">18378520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18154482">
<a name="18154482"></a>Zaffanello M, Franchini M, Fanos V. New Therapeutic Strategies With Combined Renin-Angiotensin System Inhibitors for Pediatric Nephropathy. <i>Pharmacotherapy</i>. 2008;28(1):125-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/losartan-drug-information/abstract-text/18154482/pubmed" id="18154482" target="_blank">18154482</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9574 Version 694.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
